{
    "id": 25285,
    "fullName": "EBF1 - PDGFRB",
    "impact": "fusion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "EBF1-PDGFRB results from the fusion of EBF1 and PDGFRB, demonstrating a gene expression signature similar to BCR-ABL1 and therefore, is predicted to result in a gain of function (PMID: 26703895).",
            "references": [
                {
                    "id": 6526,
                    "pubMedId": 26703895,
                    "title": "Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26703895"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1879,
        "geneSymbol": "EBF1",
        "terms": [
            "EBF1",
            "COE1",
            "EBF",
            "O/E-1",
            "OLF1"
        ]
    },
    "variant": "EBF1 - PDGFRB",
    "createDate": "08/24/2016",
    "updateDate": "08/17/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 5159,
                "geneSymbol": "PDGFRB",
                "terms": [
                    "PDGFRB",
                    "CD140B",
                    "IBGC4",
                    "IMF1",
                    "JTK12",
                    "KOGS",
                    "PDGFR",
                    "PDGFR-1",
                    "PDGFR1",
                    "PENTT"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 21159,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EBF1-PDGFRB were sensitive to treatment with CHZ868 in culture, demonstrating reduced cell viability (PMID: 29434033).",
            "molecularProfile": {
                "id": 26107,
                "profileName": "EBF1 - PDGFRB"
            },
            "therapy": {
                "id": 4016,
                "therapyName": "CHZ868",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7924,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EBF1-PDGFRB demonstrated sensitivity to treatment with Iclusig (ponatinib) in culture, resulting in decreased cell viability (PMID: 26703895).",
            "molecularProfile": {
                "id": 26107,
                "profileName": "EBF1 - PDGFRB"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6526,
                    "pubMedId": 26703895,
                    "title": "Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26703895"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7926,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EBF1-PDGFRB demonstrated sensitivity to treatment with Rebastinib (DCC-2036) in culture, resulting in decreased cell viability (PMID: 26703895).",
            "molecularProfile": {
                "id": 26107,
                "profileName": "EBF1 - PDGFRB"
            },
            "therapy": {
                "id": 1045,
                "therapyName": "Rebastinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6526,
                    "pubMedId": 26703895,
                    "title": "Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26703895"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7923,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EBF1-PDGFRB demonstrated sensitivity to treatment with Tasigna (nilotinib) in culture, resulting in decreased cell viability (PMID: 26703895).",
            "molecularProfile": {
                "id": 26107,
                "profileName": "EBF1 - PDGFRB"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6526,
                    "pubMedId": 26703895,
                    "title": "Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26703895"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7922,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EBF1-PDGFRB demonstrated sensitivity to treatment with Sprycel (dasatinib) in culture, resulting in decreased cell viability (PMID: 26703895).",
            "molecularProfile": {
                "id": 26107,
                "profileName": "EBF1 - PDGFRB"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6526,
                    "pubMedId": 26703895,
                    "title": "Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26703895"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7925,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EBF1-PDGFRB demonstrated sensitivity to treatment with Bafetinib (NS-187) in culture, resulting in decreased cell viability (PMID: 26703895).",
            "molecularProfile": {
                "id": 26107,
                "profileName": "EBF1 - PDGFRB"
            },
            "therapy": {
                "id": 661,
                "therapyName": "Bafetinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6526,
                    "pubMedId": 26703895,
                    "title": "Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26703895"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7921,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EBF1-PDGFRB demonstrated sensitivity to treatment with Gleevec (imatinib) in culture, resulting in decreased cell viability (PMID: 26703895).",
            "molecularProfile": {
                "id": 26107,
                "profileName": "EBF1 - PDGFRB"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6526,
                    "pubMedId": 26703895,
                    "title": "Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26703895"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21155,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EBF1-PDGFRB and PDGFRB D843G were resistant to treatment with Gleevec (imatinib) in culture (PMID: 29434033).",
            "molecularProfile": {
                "id": 35565,
                "profileName": "EBF1 - PDGFRB PDGFRB C843G"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21158,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EBF1-PDGFRB and PDGFRB D843G were resistant to treatment with Iclusig (ponatinib) in culture (PMID: 29434033).",
            "molecularProfile": {
                "id": 35565,
                "profileName": "EBF1 - PDGFRB PDGFRB C843G"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21160,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EBF1-PDGFRB and PDGFRB C843G were sensitive to treatment with CHZ868 in culture, demonstrating reduced cell viability (PMID: 29434033).",
            "molecularProfile": {
                "id": 35565,
                "profileName": "EBF1 - PDGFRB PDGFRB C843G"
            },
            "therapy": {
                "id": 4016,
                "therapyName": "CHZ868",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21157,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EBF1-PDGFRB and PDGFRB D843G were resistant to treatment with Tasigna (nilotinib) in culture (PMID: 29434033).",
            "molecularProfile": {
                "id": 35565,
                "profileName": "EBF1 - PDGFRB PDGFRB C843G"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21156,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EBF1-PDGFRB and PDGFRB D843G were resistant to treatment with Sprycel (dasatinib) in culture (PMID: 29434033).",
            "molecularProfile": {
                "id": 35565,
                "profileName": "EBF1 - PDGFRB PDGFRB C843G"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26107,
            "profileName": "EBF1 - PDGFRB",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35565,
            "profileName": "EBF1 - PDGFRB PDGFRB C843G",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}